Stockscreener 앱 받기
1.23
0.00%
0.00
시장 영업 전:
1.23
전일 마감가:
$1.23
열려 있는:
$1.25
하루 거래량:
334.41K
Relative Volume:
0.88
시가총액:
$120.01M
수익:
$69.56M
순이익/손실:
$-240.05M
주가수익비율:
-0.4169
EPS:
-2.95
순현금흐름:
$-121.90M
1주 성능:
+1.65%
1개월 성능:
-23.60%
6개월 성능:
-61.44%
1년 성능:
-73.72%
1일 변동 폭
$1.20
$1.26
1주일 범위
$1.13
$1.26
52주 변동 폭
$1.05
$5.17
Adc Therapeutics Sa Stock (ADCT) Company Profile
명칭
Adc Therapeutics Sa
전화
41 21 653 02 00
주소
BIOPOLE, EPALINGES
ADCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.23 | 120.01M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 개시 | Guggenheim | Buy |
| 2023-08-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-04-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 개시 | CapitalOne | Overweight |
| 2022-11-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-08-17 | 재개 | Jefferies | Buy |
| 2021-08-09 | 개시 | RBC Capital Mkts | Outperform |
| 2021-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-10-29 | 개시 | H.C. Wainwright | Buy |
| 2020-06-09 | 개시 | BofA/Merrill | Buy |
| 2020-06-09 | 개시 | Cowen | Outperform |
모두보기
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
Antibody Drug Conjugate Market to Witness Upsurge in Growth - openPR.com
Wellington Management Group LLP Purchases 84,785 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics : Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting - marketscreener.com
Sei Investments Co. Invests $46,000 in ADC Therapeutics SA (NYSE:ADCT) - The AM Reporter
Sei Investments Co. Makes New $46,000 Investment in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Prudential Financial Inc. Invests $35,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Neuroendocrine tumors Pipeline Analysis and Clinical Trials - openPR.com
SEC Form PRE 14A filed by ADC Therapeutics SA - Quantisnow
HC Wainwright Lifts Earnings Estimates for ADC Therapeutics - MarketBeat
ADC Therapeutics : 24th Annual Needham Virtual Healthcare Conference - MarketScreener
Analyzing Ratios: Adc Therapeutics SA (ADCT)’s Financial Story Unveiled - DWinneX
ADC Therapeutics SA (NYSE:ADCT) Sees Large Decline in Short Interest - MarketBeat
Research Analysts Set Expectations for ADCT Q1 Earnings - Defense World
Burkitt Lymphoma Market Expected to Witness Significant Growth by 2032 | DelveInsight - The Globe and Mail
ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
NBE Therapeutics opens ADC research facility in Switzerland - Pharmaceutical Technology
Guggenheim Has Lowered Expectations for ADC Therapeutics (NYSE:ADCT) Stock Price - MarketBeat
ADC Therapeutics' (ADCT) Buy Rating Reiterated at HC Wainwright - MarketBeat
ADCT Stock Touches 52-Week Low at $1.61 Amid Market Challenges - MSN
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Malaysian Reserve
ADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results - MarketBeat
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
ADC Therapeutics (NYSE:ADCT) Given “Buy” Rating at HC Wainwright - Defense World
ADC Therapeutics (NYSE:ADCT) Price Target Lowered to $7.00 at Guggenheim - Defense World
ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... By GuruFocus - Investing.com Canada
Guggenheim cuts ADC Therapeutics target to $7, keeps Buy rating By Investing.com - Investing.com UK
ADCT stock touches 52-week low at $1.36 amid sharp annual decline - Investing.com
Bank of New York Mellon Corp Buys 9,750 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: ADC Therapeutics Q4 2024 beats EPS, misses revenue - Investing.com Australia
ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
RBC Capital maintains Outperform on ADC Therapeutics stock By Investing.com - Investing.com UK
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates - MSN
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update - StreetInsider.com
ADC Therapeutics targets $600M–$1B in peak ZYNLONTA revenue amid expansion into DLBCL market - MSN
ADC Therapeutics SA reports results for the quarter ended December 31Earnings Summary - TradingView
ADC Therapeutics Q4 Net Income USD -30.727 Million - MarketScreener
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Finan - GuruFocus
ADC Therapeutics reports Q4 results, beats on EPS but misses revenue By Investing.com - Investing.com South Africa
ADC Therapeutics reports Q4 results, beats on EPS but misses revenue - Investing.com
ADC THERAPEUTICS SA -REDH Earnings Results: $ADCT Reports Quarterly Earnings - Nasdaq
A Preview Of ADC Therapeutics's Earnings - Benzinga
ADC Therapeutics Announces Abstracts Accepted for Presentation a - GuruFocus
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - StreetInsider
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 – Company Announcement - Financial Times
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 - Seeking Alpha
Adc Therapeutics Sa (ADCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.00%
자본화:
|
볼륨(24시간):